Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America

SummaryBackgroundThis study compared the investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate (MenACWY-D) meningococcal vaccines.MethodsIn this phase III multicenter study, 2505 adults (aged 19–55 years) were randomized to receive either MenACWY-CRM or MenACWY-D, and 326 adults (aged 56–65 years) were randomized to receive either MenACWY-CRM or MPSV4. Sera obtained pre-vaccination and at 1-month post-vaccination were tested for serogroup-specific serum bactericidal activity using human complement (hSBA) for immunogenicity non-inferiority and superiority analyses.ResultsThe vaccines in all groups were well tolerated. In the 19–55 years age group, post-vaccination geometric mean titers (GMTs) were consistently higher for MenACWY-CRM than for MenACWY-D for all four serogroups. MenACWY-CRM was non-inferior to MenACWY-D for all serogroups, and superior for serogroup Y. In the 56–65 years age group, post-vaccination GMTs were 1.2- to 5.4-fold higher for MenACWY-CRM than for MPSV4 for the four serogroups.ConclusionsMenACWY-CRM is well tolerated and immunogenic in adults aged 19–65 years, with at least non-inferior immunogenicity compared with the currently licensed meningococcal vaccines.